Lupin launches generic Minocycline Hydrochloride ER Tablets USP

Deepthi | Myequity news | Date : 26-02-2019 15:10:00 IST

Pharma major Lupin launched Minocycline Hydrochloride Extended-Release Tablets USP 55mg, having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin’s Minocycline Hydrochloride ER Tablets USP 55mg is a generic version of Medicis Pharmaceutical Corporation’s Solodyn® 55 mg. It is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.

Minocycline Hydrochloride ER Tablets USP, 55 mg (RLD: Solodyn) had annual sales of approximately USD 76.8 million in the US (IQVIA MAT December 2018).


About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.


More from Myequity